

AUG 12 2002

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: July 24, 2002

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number	09/766,678
Filing Date	01/23/2001
First Named Inventor	Axel ULLRICH et al.
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	038602-1082

RECEIVED

AUG 14 2002

TECH CENTER 1600/2000

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,185,438		Lemishka	02/08/93	
	A2	5,712,395		App et al.	01/27/98	
	A3	5,763,441		App et al.	06/09/98	
	A4	5,766,860		Terman et al.	06/16/98	
	A5	5,792,771		App et al.	08/11/98	
	A6	5,792,783		Tang et al.	08/11/98	
	A7	5,869,742		Köster et al.	02/09/99	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A8	WO	92/03459			03/05/92		
	A9	WO	92/14748			09/03/92		
	A10	WO	92/17486			10/15/92		
	A11	WO	94/10292			05/11/94		
	A12	WO	95/21868			08/17/95		
	A13	WO	96/20403			07/04/96		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A14	Breier et al., "Expression of Vascular Endothelial Growth Factor During Embryonic Angiogenesis and Endothelial Cell Differentiation," <u>Development</u> 114:521-532, 1992.	
	A15	Conn et al., "Purification of a Glycoprotein Vascular Endothelial Cell Mitogen From a Rat Glioma-derived Cell Line," <u>Proc. Natl. Acad. Sci. USA</u> 87:1323-1327, 1990.	
	A16	Connolly et al., "Human Vascular Permeability Factor. Isolation from U937 Cells," <u>The Journal of Biological Chemistry</u> , Vol. 264, No. 33, p.20021, (25 November 1989).	

Examiner Signature

Date Considered

11/13/02


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paper #9



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: July 24, 2002

(use as many sheets as necessary)

Sheet 2 of 3

**Complete if Known**

Application Number	09/766,678
Filing Date	01/23/2001
First Named Inventor	Axel ULLRICH et al.
Group Art Unit	1647
Examiner Name	Lorraine Spector
Attorney Docket Number	038602-1082

**RECEIVED****AUG 14 2002****TECH CENTER 1600/2900****OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A17	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991, 1992.	
	A18	Ferrara et al., "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochem. Biophys. Res. Comm.</u> 161:851-858, 1989.	
	A19	Ferrara et al., "The Vascular Endothelial Growth Factor Family of Polypeptides," <u>J. Cell Biochem.</u> 47:211-218, 1991.	
	A20	Gospodarowicz et al., "Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells," <u>Proc. Natl. Acad. Sci. USA</u> 86:7311-7315, 1989.	
	A21	Kashles et al., "A Dominant Negative Mutation Suppresses the Function of Normal Epidermal Growth Factor Receptors by Heterodimerization," <u>Mol. Cell. Biol.</u> 11:1454-1463, 1991.	
	A22	Klagsburn et al., "Regulators of Angiogenesis" <u>Annu. Rev. Physiol.</u> 53:217-39, 1991.	
	A23	Leung et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <u>Science</u> 246:1306-1309, 1989.	
	A24	Li et al., "Monoclonal antibodies to recombinant human vascular endothelial growth factor (rHuVEGF)," <u>Journal of Cellular Biochemistry</u> , vol. Suppl., no. 15F, p.251, (1991).	
	A25	Livneh et al., "Reconstitution of human epidermal growth factor receptors and its deletion mutants in cultured hamster cells," <u>J. Biol. Chem.</u> 261(27):12490-12497, 1986.	
	A26	Maglione et al., "Isolation of Human Placental cDNA Coding For a Protein Related to the Vascular Permeability Factor," <u>Proc. Natl. Acad. Sci. USA</u> 88:9267-9271, 1991.	
	A27	Matthews et al., "A Receptor Tyrosine Kinase cDNA Isolated From a Population of Enriched Primitive Hematopoietic Cells and Exhibiting Close Genetic Linkage to <i>c-kit</i> ," <u>Proc. Natl. Acad. Sci. USA</u> 88:9026-9030, 1991.	
	A28	McCormick, "Human gene therapy: The first round," <u>Biotechnology</u> 3(8):689-693, 1985.	
	A29	McMahon et al., "Protein kinase inhibitors: structural determinants for target specificity," <u>Current Opinions in Drug Discovery and Development</u> 1(2):131-146, 1998.	
	A30	Millaer et al., "High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis," <u>Cell</u> 72:835-846, 1993.	
	A31	Mitchell et al., "Recombinant Expression and Characterization of the 121 Amino Acid Form of Vascular Endothelial Growth Factor (VEGF)," <u>J. Cell. Biochem., Keystone Symposia on Molecular and Cellular Biology, Supplement 15C, Excerpt G207</u> , 1991.	

Examiner  
SignatureDate  
Considered


11/13/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: July 24, 2002 (use as many sheets as necessary)		<b>Complete if Known</b>		<b>RECEIVED</b> AUG 14 2002 TECH CENTER 1600/900
		Application Number	09/766,678	
Sheet	3	of	3	
		Filing Date	01/23/2001	
		First Name and Inventor	Axel ULLRICH et al.	
		Group Art Unit	1647	
		Examiner Name	Lorraine Spector	
		Attorney Docket Number	038602-1082	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
A	A32	Nicolas et al., "Retroviral Vectors," <u>Vectors</u> , Chapter 25, pp. 493-494, 1987.	
	A33	Orkin et al., "Report and Recommendations of the panel to assess the NIH investment in research on gene therapy", December 7, 1995.	
	A34	Plate et al., "Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis," <u>Cancer Research</u> 53:5822-5827, 1993.	
	A35	Prywes et al., "Mutations in the cytoplasmic domain of EGF receptor affect EGF binding and receptor internalization," <u>EMBO J.</u> 5(9):2179-2190, 1986.	
	A36	Risau et al., "Changes in the Vascular Extracellular Matrix During Embryonic Vasculogenesis and Angiogenesis," <u>Development Biology</u> 125:441-450, 1988.	
	A37	Sarzani et al., "A Novel Endothelial Tyrosine Kinase cDNA Homologous To Platelet-Derived Growth Factor Receptor cDNA" <u>Biochem. Biophys. Res. Comm.</u> 186:706-714, 1992.	
	A38	Spivak-Kroizman et al., "Heterodimerization of c-erbB2 With Different Epidermal Growth Factor Receptor Mutants Elicit Stimulatory or Inhibitory Responses," <u>J. Biol. Chem.</u> 267:8056-8063, 1992.	
	A39	Strawn et al., "Flk-1 as a Target for Tumor Growth Inhibition," <u>Cancer Research</u> 56:3540-3545, 1996.	
	A40	Tartaglia et al., <u>J. Biol. Chem.</u> 267(7), 4304-4307, March 5, 1992.	
	A41	Terman et al., "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase," <u>Oncogene</u> 6:1677-1683, 1991.	
	A42	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor," <u>Biochem. Biophys. Res. Comm.</u> 187:1579-1586, 1992.	
	A43	Traxler, "Tyrosine kinase inhibitors in cancer treatment (Part II)," <u>Exp. Opin. Ther. Patents</u> 8(12):1599-1625, 1998.	
	A44	Ueno et al., <u>J. Biol. Chem.</u> 267(3):1470-1476, January 25, 1992.	
	A45	Ueno et al., <u>Science</u> 252:844-848, May 10, 1991.	
	A46	Ullrich et al., "Signal transduction by receptors with tyrosine kinase activity", <u>Cell</u> 61:203-212, 1990.	

Examiner Signature		Date Considered	11/13/02
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.